A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

This study is currently recruiting participants.
Verified February 2013 by Hoffmann-La Roche
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01192906
First received: August 30, 2010
Last updated: February 4, 2013
Last verified: February 2013
  Purpose

This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.


Condition Intervention Phase
Schizophrenia
Drug: bitopertin [RO4917838]
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Efficacy (PANSS negative symptoms factor score) [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Safety (incidence of adverse events) [ Time Frame: Week 24 ] [ Designated as safety issue: No ]

Estimated Enrollment: 630
Study Start Date: December 2010
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: bitopertin [RO4917838]
Oral dose level 1, once a day for 52 weeks
Experimental: 2 Drug: bitopertin [RO4917838]
Oral dose level 2, once a day for 52 weeks
Placebo Comparator: 3 Drug: Placebo
Oral doses, once a day for 52 weeks

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients, aged 18 years and above
  • Diagnosis of schizophrenia of paranoid, disorganized, residual, undifferentiated or catatonic subtype
  • Predominant negative symptoms
  • With the exception of clozapine, patients are on any of the available marketed atypical or typical antipsychotics (treatment with a maximum of two antipsychotics)

Exclusion Criteria:

  • Evidence that patient has clinically significant, uncontrolled and unstable disorder (e.g. cardiovascular, renal, hepatic disorder)
  • Body Mass Index (BMI) <18.5 or >40
  • Depressive symptoms, defined as a score of 9 or greater on the Calgary Depression Rating Scale for Schizophrenia (CDSS)
  • A severity score of 3 or greater on the Parkinsonism item of the ESRS-A (Clinical Global Impression, Parkinsonism)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01192906

Contacts
Contact: Please reference Study ID Number: WN25309 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. Only) genentechclinicaltrials@druginfo.com

  Hide Study Locations
Locations
United States, California
Recruiting
Carson, California, United States, 90746
Not yet recruiting
Long Beach, California, United States, 90822
Recruiting
Oceanside, California, United States, 92056
Not yet recruiting
Oceanside, California, United States, 92056
Active, not recruiting
San Diego, California, United States, 92123
Recruiting
San Diego, California, United States, 92121
Not yet recruiting
San Diego, California, United States, 92123
United States, Connecticut
Recruiting
Hartford, Connecticut, United States, 06106
Not yet recruiting
Norwalk, Connecticut, United States, 06851
United States, Florida
Recruiting
North Miami, Florida, United States, 33161
United States, Georgia
Recruiting
Atlanta, Georgia, United States, 30328
United States, Illinois
Recruiting
Chicago, Illinois, United States, 60612
Recruiting
Hoffman Estates, Illinois, United States, 60169
Recruiting
Joliet, Illinois, United States, 60435
United States, Louisiana
Recruiting
Lake Charles, Louisiana, United States, 70601
Recruiting
Shreveport, Louisiana, United States, 71104-2136
United States, Minnesota
Not yet recruiting
Minneapolis, Minnesota, United States, 55454
United States, Missouri
Not yet recruiting
St Louis, Missouri, United States, 63118
Recruiting
St. Louis, Missouri, United States, 63110
United States, Nebraska
Recruiting
Omaha, Nebraska, United States, 68131
United States, New York
Recruiting
Cedarhurst, New York, United States, 11516
Recruiting
Jamaica, New York, United States, 11418
Recruiting
Rochester, New York, United States, 14623
United States, Pennsylvania
Recruiting
Allentown, Pennsylvania, United States, 18104
Recruiting
Norristown, Pennsylvania, United States, 19403
Recruiting
Philadelphia, Pennsylvania, United States, 19139
United States, Washington
Not yet recruiting
Bothell, Washington, United States, 98011
Brazil
Recruiting
Belo Horizonte, Brazil, 30150-270
Not yet recruiting
Criciuma, Brazil, 88806-000
Recruiting
Curitiba, Brazil, 80240-280
Active, not recruiting
Goiania, Brazil, 74922-810
Not yet recruiting
Itapira, Brazil, 13970-905
Recruiting
Pelotas, Brazil, 96030-002
Completed
Porto Alegre, Brazil, 90035-003
Recruiting
Rio de Janeiro, Brazil, 2270-060
Recruiting
Salvador, Brazil, 40301-500
Recruiting
Sao Paulo, Brazil, 05403-010
Recruiting
Sao Paulo, Brazil, 04044-000
Canada, Alberta
Recruiting
Calgary, Alberta, Canada, T2N 4Z6
Not yet recruiting
Medicine Hat, Alberta, Canada, T1B 4E7
Canada, British Columbia
Recruiting
Vancouver, British Columbia, Canada, V5Z 3P1
Recruiting
Victoria, British Columbia, Canada, V8R 1J8
Canada, Nova Scotia
Recruiting
Halifax, Nova Scotia, Canada, B3H 2E2
Canada, Ontario
Recruiting
Burlington, Ontario, Canada, L7R 4E2
Recruiting
Hamilton, Ontario, Canada, L8N 3K7
Recruiting
Mississauga, Ontario, Canada, L5M 4N4
Canada, Quebec
Recruiting
Montreal, Quebec, Canada, H3A 1A1
Recruiting
Montreal, Quebec, Canada, H4H IR3
Recruiting
Montreal, Quebec, Canada, H1N 3M5
Chile
Recruiting
Santiago, Chile
Recruiting
Santiago, Chile, 8320000
Recruiting
Santiago, Chile, 8900000
Recruiting
Santiago, Chile, 8050000
Recruiting
Valdivia, Chile, 5090000
Germany
Not yet recruiting
Berlin, Germany, 10117
Recruiting
Bochum, Germany, 44805
Recruiting
Freiburg, Germany, 79104
Not yet recruiting
Hamburg, Germany, 20246
Recruiting
Koeln, Germany, 50924
Recruiting
Muenchen, Germany, 80336
Recruiting
Muenchen, Germany, 81675
Recruiting
Nurenberg, Germany, 90402
Not yet recruiting
Siegen, Germany, 57072
Not yet recruiting
Werneck, Germany, 97440
Latvia
Not yet recruiting
Daugavpils, Latvia, 5417
Recruiting
Daugavpils, Latvia, 5417
Not yet recruiting
Jelgava, Latvia, LV-3008
Recruiting
Liepaja, Latvia, 3401
Lithuania
Recruiting
Kaunas, Lithuania, 53136
Terminated
Kaunas, Lithuania, 50009
Recruiting
Kaunas, Lithuania, 48259
Recruiting
Kaunas, Lithuania, 50185
Recruiting
Silute, Lithuania, 99142
Recruiting
Vilnius, Lithuania, 07156
Recruiting
Vilnius, Lithuania, 10204
Netherlands
Recruiting
Assen, Netherlands, 9400 RA
Recruiting
Groningen, Netherlands, 9713 GZ
Recruiting
Groningen, Netherlands, 9725 AG
Poland
Recruiting
Choroszcz, Poland, 16-070
Recruiting
Kielce, Poland, 25-317
Recruiting
Lublin, Poland, 20-582
Not yet recruiting
Lublin, Poland, 20-045
Recruiting
Lublin, Poland, 20-109
Recruiting
Piekary Slaskie, Poland, 41-940
Recruiting
Skorzewo, Poland, 60-165
Recruiting
Tuszyn, Poland, 95-080
Recruiting
Warszawa, Poland, 02-957
Slovakia
Recruiting
Bojnice, Slovakia, 972 01
Recruiting
Bratislava, Slovakia, 851 01
Recruiting
Bratislava, Slovakia, 820 07
Not yet recruiting
Michalovce, Slovakia, 071 01
Not yet recruiting
Rimavska Sobota, Slovakia, 979 01
Not yet recruiting
Rimavska Sobota, Slovakia, 979 12
Recruiting
Svidnik, Slovakia, 089 01
Recruiting
Trnava, Slovakia, 917 75
Spain
Recruiting
Barcelona, Spain, 08036
Recruiting
Barcelona, Spain, 08830
Recruiting
Barcelona, Spain, 08304
Terminated
Madrid, Spain, 28040
Recruiting
Madrid, Spain, 28009
Recruiting
Oviedo, Spain, 33011
Recruiting
Salamanca, Spain, 37007
Recruiting
Zamora, Spain, 49021
Taiwan
Recruiting
Hualien, Taiwan, 981
Recruiting
Kaohsiung, Taiwan, 802
Recruiting
Tainan, Taiwan, 704
Recruiting
Tainan County, Taiwan, 717
Recruiting
Taipei, Taiwan, 112
Recruiting
Taipei, Taiwan, 110
Recruiting
Taiwan, Taiwan, 407
Turkey
Not yet recruiting
Ankara, Turkey, 06100
Recruiting
Ankara, Turkey, 06100
Recruiting
Diyarbakir, Turkey, 10000
Recruiting
Gaziantep, Turkey, 27310
Recruiting
Istanbul, Turkey, 34736
Recruiting
Istanbul, Turkey, 34390
Not yet recruiting
Istanbul, Turkey, 34098
Not yet recruiting
Izmir, Turkey, 35340
Not yet recruiting
Kocaeli, Turkey, 41380
Recruiting
Manisa, Turkey, 45010
Not yet recruiting
Mersin, Turkey, 33169
Ukraine
Recruiting
Dnipropetrovsk, Ukraine, 49005
Recruiting
Donetsk, Ukraine, 83008
Recruiting
Glevakha Kyviv Region, Ukraine, 08631
Recruiting
Kharkiv, Ukraine, 61068
Not yet recruiting
Kiev, Ukraine, 01030
Recruiting
Kyiv, Ukraine, 04080
Recruiting
Kyiv, Ukraine, 02660
Recruiting
Lviv, Ukraine, 79021
Recruiting
Odessa, Ukraine, 65006
Recruiting
Vinnytsya, Ukraine, 21005
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01192906     History of Changes
Other Study ID Numbers: WN25309, 2010-020467-21
Study First Received: August 30, 2010
Last Updated: February 4, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders

ClinicalTrials.gov processed this record on May 23, 2013